Compare Novavax Inc (NVAX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Smith & Nephew plc — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc is far larger — about 9.7× Novavax Inc's market cap, and Smith & Nephew plc pays a 2.57% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SNN | |
|---|---|---|
Market Cap | $1.30B | $12.64B |
Sector | Health | Health |
52-Week High | $11.19 | $38.70 |
52-Week Low | $6.22 | $28.73 |
Enterprise Value | $800.50M | $15.41B |
Dividend Yield | — | 2.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
